Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Ticker SymbolBBNX
Company nameBeta Bionics Inc
IPO dateJan 30, 2025
CEOMr. Sean Saint
Number of employees291
Security typeOrdinary Share
Fiscal year-endJan 30
Address11 Hughes
CityIRVINE
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code92618
Phone19494277785
Websitehttps://www.betabionics.com
Ticker SymbolBBNX
IPO dateJan 30, 2025
CEOMr. Sean Saint
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data